1. Remove the vial from freezer storage and allow to equilibrate at room temperature for 15 to 20 minutes.
2. Draw 2.5 mL bacteriostatic water with a sterile syringe.
3. Inject slowly down the vial wall; avoid foaming.
4. Gently swirl until dissolved (solution should be clear; do not shake).
5. Label and refrigerate at 2 to 8 °C, protected from light; use within 2 to 4 weeks. At 20 mg/mL, 1 unit = 0.01 mL = 0.2 mg (200 mcg) on a U-100 insulin syringe.

5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small molecule that selectively inhibits Nicotinamide N-methyltransferase (NNMT). NNMT is an enzyme that methylates nicotinamide (vitamin B3) using S-adenosylmethionine (SAM) as a methyl donor. In states of obesity and metabolic dysfunction, NNMT is often overexpressed in adipose tissue, depleting nicotinamide and reducing NAD+ availability. By inhibiting NNMT, 5-Amino-1MQ may spare nicotinamide for NAD+ synthesis, thereby activating SIRT1 (Sirtuin 1) pathways associated with mitochondrial biogenesis and fat oxidation. Preclinical studies indicate that NNMT knockdown or inhibition can protect against diet-induced weight gain and improve metabolic parameters without reducing food intake.

• May support reductions in fat mass while preserving lean muscle in animal models.
• Associated with elevated NAD+ levels and SIRT1 activation in preclinical studies.
• Enhanced grip strength observed in aged mice when combined with exercise.
• Generally well tolerated; occasional reports of mild headache, transient jitteriness, or injection-site
  reactions.
• Long-term human safety data not established; this compound remains investigational.